Form 4: Helius Medical Technologies CEO Granted 52,400 Stock Options Under Equity Plan

Helius Medical Technologies, Inc. (HSDT) reports that its President and CEO, Dane Andreeff, was granted 52,400 stock options with an exercise price of $9.76 under the company's 2022 Equity Incentive Plan.

Summary

• Dane Andreeff, President and CEO, Director, and 10% Owner of Helius Medical Technologies, Inc. (HSDT), was granted 52,400 stock options.
• The options were granted on July 2, 2025, under the Issuer's 2022 Equity Incentive Plan.
• The exercise price for these options is $9.76 per share.
• The options have an expiration date of July 1, 2035.
• 50% of the granted options vested immediately upon grant.
• The remaining 50% will vest in twelve equal quarterly installments, beginning on September 30, 2025, contingent on Mr. Andreeff's continued service.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive sign of management alignment and retention, though it's a routine compensation event rather than a significant operational announcement.

Positives

• The grant of stock options aligns the interests of the President and CEO, Dane Andreeff, with those of shareholders, incentivizing long-term company performance.
• The immediate vesting of 50% of the options provides immediate incentive, while the quarterly vesting schedule encourages continued service and commitment.

Negatives

• The issuance of new stock options could potentially lead to future share dilution if exercised, though this is a standard component of executive compensation plans.

Risks

• The value of the stock options is subject to the future market price of Helius Medical Technologies, Inc. Class A Common Stock, which may fluctuate.
• Vesting of the remaining options is contingent upon the reporting person's continued service, introducing a dependency on employment status.

Future Outlook

The future value of the stock options is dependent on the company's stock performance and the continued service of the President and CEO through the vesting periods.

Industry Context

This is a standard executive compensation event within the medical technology sector, aiming to align management incentives with shareholder value creation. Such grants are common practice across industries to retain and motivate key executives.

Related Party Transactions

• Grant of stock options to Dane Andreeff, who serves as President and CEO, Director, and 10% Owner, under the company's 2022 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value if the options incentivize strong company performance.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.

Next Steps

• Continued vesting of the remaining 50% of stock options in twelve equal quarterly installments, subject to Dane Andreeff's continued service.
• Potential exercise of vested stock options by Dane Andreeff in the future.

Key Dates

Keywords

Helius Medical Technologies, HSDT, Dane Andreeff, Stock Options, Equity Incentive Plan, Executive Compensation, SEC Form 4, Insider Transaction, Director, CEO, 10% Owner